Results 11 to 20 of about 16,343,665 (315)
GSK-3 inhibitors: preclinical and clinical focus on CNS [PDF]
Frontiers in Molecular Neuroscience, 2011 Inhibiting glycogen synthase kinase-3 (GSK-3) activity via pharmacological intervention has become an important target for treating neurodegenerative and psychiatric disorders.
Hagit eEldar-Finkelman, Ana eMartinez
doaj +5 more sources
The GSK-3 Inhibitor CT99021 Enhances the Acquisition of Spatial Learning and the Accuracy of Spatial Memory [PDF]
Frontiers in Molecular Neuroscience, 2022 Glycogen synthase kinase 3 (GSK-3) is a Ser/Thr protein kinase that regulates many cellular processes, including synaptic plasticity. Previously, we reported that inhibition of GSK-3 prevents the induction of one of the major forms of synaptic plasticity,
Yeseul Lee +18 more
doaj +2 more sources
Cell, 2001 The structure, biochemistry and effect of mutagenesis suggest a more complex regulation of GSK-3 than previously imagined. This protein kinase is able to process at least two different stimuli and deliver distinct outcomes. This in part may be due to compartmentalization of GSK-3 action within the cell, but what these recent results suggest is that ...
Adrian J. Harwood
openalex +5 more sources
GSK-3 and Wnt signaling in neurogenesis and bipolar disorder [PDF]
Frontiers in Molecular Neuroscience, 2012 The Wnt signaling pathway is critical for development of the mammalian central nervous system and regulates diverse processes throughout adulthood, including adult neurogenesis. Glycogen Synthase Kinase-3 (GSK-3) antagonizes the Wnt pathway and therefore
Alexander J Valvezan +2 more
doaj +4 more sources
GSK-3 inhibitors induce chromosome instability [PDF]
BMC Cell Biology, 2007 Background Several mechanisms operate during mitosis to ensure accurate chromosome segregation. However, during tumour evolution these mechanisms go awry resulting in chromosome instability.
Staples Oliver D +3 more
doaj +4 more sources
Modulation of GSK-3 as a therapeutic strategy on Tau pathologies [PDF]
Frontiers in Molecular Neuroscience, 2011 Glycogen synthase kinase 3 (GSK-3) is ubiquitously expressed and unusually active in resting, non-stimulated cells. In mammals, at least three proteins (, and generated from two different genes, gsk3 and gsk3 are widely expressed at both the
Miguel eMedina +2 more
doaj +9 more sources
Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6
eLife, 2014 Glycogen synthase kinase-3 (GSK-3) is a key regulator of many cellular signaling pathways. Unlike most kinases, GSK-3 is controlled by inhibition rather than by specific activation.
Jennifer L Stamos +4 more
doaj +2 more sources
GSK-3 as potential target for therapeutic intervention in cancer
Oncotarget, 2014 The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. GSK-3 functions in a wide range of cellular processes.
J. McCubrey +17 more
semanticscholar +9 more sources
eLife, 2014 GSK-3 is an essential mediator of several signaling pathways that regulate cortical development. We therefore created conditional mouse mutants lacking both GSK-3α and GSK-3β in newly born cortical excitatory neurons.
Meghan Morgan-Smith +4 more
doaj +2 more sources
GSK‐3 in Neurodegenerative Diseases [PDF]
International Journal of Alzheimer’s Disease, 2011 Glycogen synthase kinase‐3 (GSK‐3) regulates multiple cellular processes, and its dysregulation is implicated in the pathogenesis of diverse diseases. In this paper we will focus on the dysfunction of GSK‐3 in Alzheimer’s disease and Parkinson’s disease. Specifically, GSK‐3 is known to interact with tau, β‐amyloid (Aβ), and α‐synuclein, and as such may
Peng Lei +3 more
openalex +6 more sources